Aim: To evaluate the efficacy and safety of using the drug Voltaren Emulgel 2% (diclofenac diethylaminе 2%) for 14 days in patients with osteoarthritis (OA) of small joints of the hands.
Materials And Methods: 62 patients of both sexes with hands OA were included in the study, 31 of whom (main group) used Voltaren Emulgel 2% (diclofenac diethylaminе 2%) topically, and the remaining 31 (comparison group) Voltaren Emulgel 2% (diclofenac diethylamine 2%) + oral nonsteroidal anti-inflammatory drugs. The effectiveness of therapy was assessed by using a visual analogue scale (VAS) in dynamics: joint pain and stiffness at rest, pain on movement and during palpation, by functional indices AUSCAN, FIHOA, by assessment of the effect of therapy by the doctor and the patient on a weekly basis.
Results And Discussion: Joint pain decreased after 2 weeks of therapy in all patients during treatment with Voltaren Emulgel 2% (diclofenac diethylamine 2%) in both groups. Significant reduction in stiffness and improvement in hand joint function was achieved after 7 days and lasted until the end of treatment. By the end of treatment, 100% of patients assessed their condition as improvement.
Conclusion: Voltaren Emulgel 2% (diclofenac diethylamine 2%) demonstrates comparable clinical efficacy in patients with OA of the hand joints (reduced pain, stiffness and improved joint function) in monotherapy as complex therapy in combination with oral NSAIDS, while being well tolerated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.26442/00403660.2021.05.200846 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Objective: To explore the clinical effect of personalized brace based on 3D printing technology in the treatment of stenosing tenosynovitis.
Methods: From September 2021 to June 2023, 20 patients with stenosing tenosynovitis were collected and randomly divided into the experimental group and the control group, with 10 cases in each group, and each patient signed an informed consent. The experimental group was treated with personalized brace combined with External Diclofenac Diethalamine Emulgel, and the control group was treated with External Diclofenac Diethalamine Emulgel, and the clinical efficacy and pain scores of the two groups were compared.
Development and Evaluation of Nano-Vesicular Emulsion-Based Gel as a Promising Approach for Dermal Atorvastatin Delivery Against Inflammation.
Int J Nanomedicine
November 2024
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Modern University for Technology and Information, Cairo, 4410240, Egypt.
Introduction: Atorvastatin (ATV), a medication used to reduce cholesterol levels, possesses properties that can counteract the damaging effects of free radicals and reduce inflammation. However, the administration of ATV orally is associated with low systemic bioavailability due to its limited capacity to dissolve in water and significant first-pass effect. This study aimed to assess the appropriateness of employing nano-vesicles for transdermal administration of ATV in order to enhance its anti-inflammatory effects.
View Article and Find Full Text PDFArtemisinin emulgel ameliorates cartilage degradation in knee osteoarthritis: and studies.
Ther Deliv
November 2024
Department of Pharmaceutics, National Institute of Pharmaceutical Education & Research, Hyderabad, Telangana, India.
Laboratory scale-up of artemisinin-loaded emulgel (ART-emulgel) was carried out and characterized for therapeutic performance in osteoarthritis (OA). The solubility of ART in various oils, surfactants and co-surfactants were screened for construction of pseudo ternary phase diagram (TPD), followed by scale-up of artemisinin loaded nanoemulsion (ART-NE). ART-NE was amalgamated with Carbopol Ultrez 10-NF to prepare ART-emulgel that was later characterized and to analyze therapeutic efficacy in monosodium-iodoacetate (MIA) induced knee OA.
View Article and Find Full Text PDFAlternatives to Conventional Topical Dosage Forms for Targeted Skin Penetration of Diclofenac Sodium.
Int J Mol Sci
July 2024
Research & Innovation, Seppic, 127 Chemin de la Poudrerie, 81100 Castres, France.
Skin penetration of an active pharmaceutical ingredient is key to developing topical drugs. This penetration can be adjusted for greater efficacy and/or safety through the selection of dosage form. Two emerging dosage forms, cream-gel and gel-in-oil emulsion, were tested for their ability to deliver diclofenac into the skin, with the target of maximising skin retention while limiting systemic exposure.
View Article and Find Full Text PDFImpact of Time on Parameters for Assessing the Microstructure Equivalence of Topical Products: Diclofenac 1% Emulsion as a Case Study.
Pharmaceutics
June 2024
Departamento de Farmacia y Tecnología Farmacéutica y Parasitología, Universidad de Valencia, Avda. Vicent Andrés Estellés s/n, Burjasot, 46100 Valencia, Spain.
The demonstration of bioequivalence proposed in the European Medicines Agency's (EMA's) draft guideline for topical products with the same qualitative and quantitative composition requires the confirmation of the internal structure equivalence. The impact of the shelf-life on the parameters proposed for internal structure comparison has not been studied. The objectives of this work were: (1) to quantify the effect of the time since manufacturing on the mean value and variability of the parameters proposed by the EMA to characterize the internal structure and performance of topical formulations of a complex topical formulation, and (2) to evaluate the impact of these changes on the assessment of the microstructure equivalence.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!